Life Sciences Series: Therapeutic Focus: A Mouse Trap Without the Mouse: The New Frontiers in Bio-Safety Models
Before the testing of an experimental drug in humans can commence, it has to fulfill certain efficacy and undoubtedly conform to the established safety criteria. Both in vitro and in vivo tests are performed to assess the drug’s toxicity and safety margins. Traditionally animal models are used to predict ultimately a product’s safety in humans. Increasingly alternatives emerge, such as predictive computer, cellular and tissue models. The development of reliable tools suitable for industrial applications not only promises to do this at a fraction of the cost and time, but be potentially identifying health risks more reliably than even human pivotal trials and without the usually associated liability. A panel of company representatives will examine use of traditional vs. alternative models: pros and cons, reliability and variability, costs and viability, as well as FDA and EMA approval process impact.
Partner, Reed Smith LLP
Vice President of R&D,
Dale E. Johnson, PharmD, PhD
President & CEO,
Moo Yeal Lee
Solidus Biosciences, Inc.
David A. Lustig, Ph.D.
VP, Business Development
Optivia Biotechnology Inc.
A Mouse Trap Without the Mouse:
The New Frontiers in Bio-Safety Models
|When:||Thursday, February 17, 2011
Registration Opens: 3:30pm
Panel Discussion: 4:00pm – 5:30pm
Networking Reception: 5:30pm – 6:30pm
|Where:||South San Francisco Conference Center
255 South Airport Blvd.
South San Francisco, CA
|Parking:||Multiple Lot Options|
|Getting There:||Public Transportation Information|
|Cost:||Pre-registration through February 16
$20 BayBio Members | $40 Non-Members
On-site registration on February 17
$40 BayBio Members | $75 Non-Members
|Attire:||Business attire suggested|